PBAC's latest decision on House dust mite allergen extract: Recommended with restriction (2016). Considered for Treatment of allergic rhinitis caused by house dust mites in adults and adolescents above 12 years with moderate to severe symptoms inadequately controlled or intolerant to symptomatic treatments.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2016
Submissions
1
2016 → 2016
Eligible population
Adults and adolescents above 12 years with moderate to severe allergic rhinitis due to house dust mites who have inadequate response or intolerance to antihistamines and nasal corticosteroids after 12 months of trial.
Therapy area
Immunology
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
Symptom score
Pivotal trial size
509 patients
Key trials
VO57.07, 1207d1731, VO64.08, VO67.10, MT-06
Comparator
placebo
ICER note
No ICER was calculated. The submission was based on a cost-effectiveness comparison with placebo, but the PSD does not report a numeric ICER value.